Randomised, multicentre trial of XXXX vs. an institutional standard regimen for salvage treatment of @entity3 .

@entity1331 @entity1 @entity2379 @entity5074 @entity3 @entity204 @entity11794
@entity3 remains associated with significant morbidity and mortality, necessitating new options for salvage therapy. The objective of this study was to evaluate the efficacy and safety of @entity1331 as salvage monotherapy in @entity1 with @entity3 . @entity1 with proven or probable @entity3 , who were refractory or intolerant to previous systemic antifungal therapy, were randomised 2  :  1 to receive 300  mg  day(-1) intravenous @entity1331 monotherapy or an intravenous control monotherapy [lipid @entity2379 (5  mg  kg(-1)   day(-1) ), @entity5074 (8  mg  kg(-1)   day(-1) ) or @entity11794 (50  mg  day(-1) )] for 3-12  weeks. @entity1 underwent final assessment 12  weeks after treatment start. Seventeen @entity1 with @entity3 (proven, n  =  2; probable, n  =  14; not recorded, n  =  1) participated in the study ( @entity1331 arm, n  =  12; control arm, n  =  5). Three @entity1 each in the @entity1331 (25.0%; 95% CI: 5.5-57.2) and control arm (60.0%; 95% CI: 14.7-94.7) had successful therapy at end of treatment as assessed by an Independent Data Review Board. Eleven @entity1 died; six due to @entity3 . No @entity204 were considered related to study treatment. During this study it became increasingly common to use combination treatment for salvage therapy. Consequently, enrolment was low and the study was discontinued early. No clear trends in efficacy and safety can be concluded.
